CTLA-4 Antibody (L4P2F5*F10) - BSA Free

Novus Biologicals | Catalog # NBP2-50286

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

Human, Mouse, Rat, Bovine

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, ELISA

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # L4P2F5*F10

Format

BSA Free
View all CTLA-4 Primary Antibodies »

Product Specifications

Immunogen

Ovalbumin-conjugated synthetic peptide CENAPNRARM

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Description

The clone number is listed as L4P2F5*F10 in the scientific literature.

Scientific Data Images for CTLA-4 Antibody (L4P2F5*F10) - BSA Free

Western Blot: CTLA-4 Antibody (L4P2F5*F10)BSA Free [NBP2-50286]

Western Blot: CTLA-4 Antibody (L4P2F5*F10)BSA Free [NBP2-50286]

Western Blot: CTLA-4 Antibody (L4P2F5*F10) [NBP2-50286] - Analysis of CTLA-4 in Jurkat cell lysates. Two products are detected, slightly larger than anticipated-possibly due to glycosylation.
Immunohistochemistry-Paraffin: CTLA-4 Antibody (L4P2F5*F10) - BSA Free [NBP2-50286]

Immunohistochemistry-Paraffin: CTLA-4 Antibody (L4P2F5*F10) - BSA Free [NBP2-50286]

Immunohistochemistry-Paraffin: CTLA-4 Antibody (L4P2F5*F10) [NBP2-50286] - Human lymph node cross section. Cytoplasmic staining is shown as expected (CTLA4 is expressed in T-cells). B. Positive cytoplasmic staining was also detected in human breast cancer sections.
ELISA: CTLA-4 Antibody (L4P2F5*F10) - BSA Free [NBP2-50286]

ELISA: CTLA-4 Antibody (L4P2F5*F10) - BSA Free [NBP2-50286]

ELISA: CTLA-4 Antibody (L4P2F5*F10) [NBP2-50286] - Detection of soluble CTLA4 in mouse serum by indirect ELISA.
CTLA-4 Antibody (L4P2F5*F10) - BSA Free

Immunohistochemistry-Paraffin: Mouse Monoclonal CTLA-4 Antibody (L4P2F5*F10) [NBP2-50286] -

Immunohistochemistry-Paraffin: Mouse Monoclonal CTLA-4 Antibody (L4P2F5*F10) [NBP2-50286] - CTLA-4 was stained in human tonsil FFPE tissue. HIER antigen retrieval at pH 9 for 20min. Antibody was used in concentrations between 1:50-100. AF750 conjugated version of antibody was used (Catalog # NBP2-50286AF750). Image from a verified customer review.

Applications for CTLA-4 Antibody (L4P2F5*F10) - BSA Free

Application
Recommended Usage

ELISA

1:100 - 1:2000

Immunohistochemistry

1:10 - 1:500

Western Blot

1:100 - 1:2000
Application Notes
Positive control(s): IHC- formalin-fixed, paraffin-embedded multi tumour tissue microarray; WB - Jurkat cell lysates.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CTLA-4

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), also known as CD152, is a cell surface glycoprotein belonging to the immunoglobulin family with a role in regulation of T cell activation (1). Human CTLA-4 is a 223 amino acid (aa) protein with a theoretical molecular weight of 24.6 kDa containing a leader peptide, a IgV-like domain, a transmembrane domain, and a cytoplasmic tail (1,2). CTLA-4 is both structurally and functionally related with another member of the immunoglobulin-related receptor family, CD28 (1-3). CTLA-4 and CD28 receptors are both expressed by CD4+ and CD8+ T cells and share two common ligands, CD80 (B7.1) and CD86 (B7.2), expressed on the surface of antigen presenting cells (APCs) (2,3). While CD28 is present on the plasma membrane of T cells, CTLA-4 is predominantly expressed intracellularly on vesicles in FoxP3+ regulatory T (Treg) cells and activated T cells due to endocytosis (3). While they share ligands, the two receptors have opposing functions in T cell activation; CD28 is involved in activation of T cells, while CTLA-4 functions as a negative regulator of T cell response (2,3). One of the primary functions of CTLA-4 is preventing autoimmunity (1-4).

Similar to programmed cell death protein 1 (PD-1), CTLA-4 is an inhibitory immune checkpoint protein (3,5). Checkpoint blockade immunotherapy using drugs or antibodies to target CTLA-4 is one of the main approaches for cancer treatment (5). A number of drugs targeting CTLA-4, or a combination of CTLA-4/PD-1, have been approved for treatment of various cancers like melanoma, renal cell carcinoma, and colorectal cancer (5). While blocking CTLA-4 in the tumor microenvironment is a promising cancer therapeutic, the absence of CTLA-4 under normal conditions can have deleterious effects. Studies have found that patients with CTLA-4 deficiency or mutations have clinical features associated with autoimmunity and immune dysregulation (4). Treatment options for CTLA-4 deficiency includes immunoglobulin-replacement therapy, corticosteroids, CTLA-4-immunoglobulin (Ig) fusion protein, and, in life-threatening cases, hematopoietic stem cell transplantation (4,6). Additionally, engaging CD80/CD86 with CTLA-4-Ig is a common immunosuppressive treatment for rheumatoid arthritis and kidney transplant recipients (6).

References

1. Romo-Tena, J., Gomez-Martin, D., & Alcocer-Varela, J. (2013). CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmunity reviews, 12(12), 1171-1176. https://doi.org/10.1016/j.autrev.2013.07.002

2. Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020). CTLA-4: From mechanism to autoimmune therapy. International immunopharmacology, 80, 106221. https://doi.org/10.1016/j.intimp.2020.106221

3. Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018). CTLA-4: a moving target in immunotherapy. Blood, 131(1), 58-67. https://doi.org/10.1182/blood-2017-06-741033

4. Verma, N., Burns, S. O., Walker, L., & Sansom, D. M. (2017). Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clinical and experimental immunology, 190(1), 1-7. https://doi.org/10.1111/cei.12997

5. Rotte A. (2019). Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of experimental & clinical cancer research : CR, 38(1), 255. https://doi.org/10.1186/s13046-019-1259-z

6. Bluestone, J. A., St Clair, E. W., & Turka, L. A. (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity, 24(3), 233-238. https://doi.org/10.1016/j.immuni.2006.03.001

Long Name

Cytotoxic T-lymphocyte-associated Molecule 4

Alternate Names

CD152, CTLA4

Gene Symbol

CTLA4

Additional CTLA-4 Products

Product Documents for CTLA-4 Antibody (L4P2F5*F10) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for CTLA-4 Antibody (L4P2F5*F10) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews for CTLA-4 Antibody (L4P2F5*F10) - BSA Free

There are currently no reviews for this product. Be the first to review CTLA-4 Antibody (L4P2F5*F10) - BSA Free and earn rewards!

Have you used CTLA-4 Antibody (L4P2F5*F10) - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies